Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2022–Rheonix announced that the FDA has granted 510(k) clearance for its automated Encompass MDx Workstation along with its STI TriPlex assay and Male Urine Collection Kit for the detection of sexually transmitted infections. The molecular testing device is a closed system that is automated from sample loading to result reporting, provides direct tube sampling, and contains all the reagents needed.
April 2022—Qiagen announced test enhancements to its QIAstat-Dx, a fully integrated molecular diagnostic testing solution with one-step sample processing that provides results in about one hour. The company is awaiting U.S. regulatory approval of a gastrointestinal panel designed to detect 22 common viral, bacterial, and parasitic pathogens that can cause potentially life-threatening infections. Qiagen has also registered for CE marking a meningitis/encephalitis panel designed to analyze 15 pathogens simultaneously and help distinguish between meningitis and encephalitis.
April 2022—The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting. The treatment is approved regardless of PD-L1 status and is based on the CheckMate -816 trial, the first positive phase three trial of an immunotherapy-based combination used before surgery for resectable NSCLC.
April 2022—Beckman Coulter Life Sciences has entered into an agreement with AmoyDx to develop applications on the Biomek NGenius liquid handling system. The Biomek NGenius system is scheduled to launch in the second quarter of this year; it is not intended or validated for use in diagnosis of disease or other conditions.
April 2022—Roche launched its Avenio Edge System, an all-in-one preanalytical platform that is designed to minimize manual touchpoints and includes ready-to-load reagents, validated protocols, onboard capabilities, and intuitive software to manage next-generation sequencing sample workflows.
April 2022—Roche announced the launch of the Cobas Pulse system, the company’s newest generation of connected POC solutions for professional blood glucose management, in select countries accepting the CE mark.
April 2022—Tribun Health announced it won a 2022 “Best in KLAS” award for digital pathology in Europe. The Best in KLAS report from KLAS Research recognizes software and services companies that excel in helping health care professionals improve patient care.
March 2022—Qiagen announced expansion initiatives for its QuantiFeron portfolio, including developing new applications for technology designed to detect potentially deadly latent diseases. Among the company’s recent developments are the CE marking of its QuantiFeron SARS-CoV-2 assay, which launched in December 2021; the FDA’s expansion of the range of target groups that can be tested with the blood-based QuantiFeron-TB Gold assay, which now includes people with weakened immune systems, pregnant women, and children; and the Global Fund’s expert review panel for diagnostics’ approval of the QIAreach QuantiFeron-TB test, which means the test may now be procured by public health programs and institutions in more than 100 countries that qualify for Global Fund and Unitaid resources, as well as made available through the Stop TB Partnership’s Global Drug Facility.
March 2022—Beckman Coulter Life Sciences has signed an agreement with Illumina to develop applications on the Biomek NGeniuS Next Generation Library Preparation System, which is scheduled to launch during the second quarter of this year. The applications will be available to Biomek NGeniuS system users via a first-of-its-kind electronic application library, the company says.
March 2022—Asuragen has launched a kit to detect pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The AmplideX PCR/CE CFTR Kit, for research use only, is designed to detect about 93 percent of CFTR pathogenic variants observed in the U.S. population.
